UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 387

Sortiert nach

Cancer Stem Cells: The Promise and the Potential

Seminars in oncology, 2015-04, Vol.42, p.S3-S17

2015

Volltextzugriff (PDF)

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Blood, 2022-03, Vol.139 (11), p.1684-1693

2022

Volltextzugriff (PDF)

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

PloS one, 2013-03, Vol.8 (3), p.e54014

2013

Volltextzugriff (PDF)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359221146137-17588359221146137

2023

Volltextzugriff (PDF)

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Journal of clinical oncology, 2008-07, Vol.26 (21), p.3523-3529

2008

Volltextzugriff (PDF)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

BMC cancer, 2016-07, Vol.16 (1), p.467-467, Article 467

2016

Volltextzugriff (PDF)

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

Journal of clinical oncology, 2007-10, Vol.25 (29), p.4557-4561

2007

Volltextzugriff (PDF)

Routine DPYD Genetic Testing

Journal of clinical oncology, 2023-04, Vol.41 (11), p.2119-2120

Hochster, Howard S

2023

Volltextzugriff (PDF)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

PloS one, 2022-10, Vol.17 (10), p.e0276211-e0276211

2022

Volltextzugriff (PDF)

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity

Journal of clinical oncology, 2007-09, Vol.25 (25), p.4028-4029

2007

Volltextzugriff (PDF)

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

Medical oncology (Northwood, London, England), 2013-03, Vol.30 (1), p.361-7, Article 361

2013

Volltextzugriff (PDF)

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

PloS one, 2021-12, Vol.16 (12), p.e0261994-e0261994

2021

Volltextzugriff (PDF)

Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research

Current oncology (Toronto), 2023-07, Vol.30 (7), p.6432-6446

2023

Volltextzugriff (PDF)

Chemotherapy Drug Shortages: It's Soluble

Oncology (Williston Park, N.Y.), 2023-11, Vol.37 (11), p.446

Hochster, Howard S

2023

Volltextzugriff (PDF)

Drug Price Negotiations: One Long-Overdue "Small Step" for the American Health Care Consumer

Oncology (Williston Park, N.Y.), 2023-09, Vol.37 (9), p.364

Hochster, Howard S

2023

Volltextzugriff (PDF)

PROSPECT: A Study Whose Time Is Past

Oncology (Williston Park, N.Y.), 2023-07, Vol.37 (7), p.273

Hochster, Howard S

2023

Volltextzugriff (PDF)

The Painful Problem of Biosimilars in the Clinic

Oncology (Williston Park, N.Y.), 2023-05, Vol.37 (5)

Hochster, Howard S

2023

Volltextzugriff (PDF)

Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GI

Oncology (Williston Park, N.Y.), 2023-03, Vol.37 (3), p.96

Hochster, Howard S

2023

Volltextzugriff (PDF)

Increasing Breast Cancer Diagnosis in Rural Areas and the Evolving Access to Health Care

Oncology (Williston Park, N.Y.), 2023-01, Vol.37 (1), p.7

Hochster, Howard S

2023

Volltextzugriff (PDF)

2022 The Oncology Year in Review

Oncology (Williston Park, N.Y.), 2022-12, Vol.36 (12), p.704

Hochster, Howard S

2022

Volltextzugriff (PDF)

Is Drug Price Negotiation a Concept Whose Time Has Come?

Oncology (Williston Park, N.Y.), 2022-09, Vol.36 (9), p.523

Hochster, Howard S

2022

Volltextzugriff (PDF)

Platinum Hypersensitivity Reaction : An Ongoing Problem in Cancer Treatment

Oncology (Williston Park, N.Y.), 2022-07, Vol.36 (7), p.406

Hochster, Howard S

2022

Volltextzugriff (PDF)

CRISPR Patent Battle: Beautiful Science, Poor Public Policy

Oncology (Williston Park, N.Y.), 2022-05, Vol.36 (5), p.263

Hochster, Howard S

2022

Volltextzugriff (PDF)

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

Cancer medicine (Malden, MA), 2023-10, Vol.12 (20), p.20353-20364

2023

Volltextzugriff (PDF)

1 – 25 von 387

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(375)
Mit Volltextzugriff
(360)

Publikationsform

Artikel
(386)
Buchkapitel
(1)

Sprache

Englisch
(387)
Japanisch
(25)

Erscheinungsjahr

n.n

Thema

Science & Technology
(184)
Life Sciences & Biomedicine
(182)
Oncology
(158)
Humans
(156)
Female
(101)
Male
(89)
Aged
(86)
Middle Aged
(86)
Adult
(75)
Biological And Medical Sciences
(53)
Medical Sciences
(53)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(52)
Chemotherapy
(51)
Treatment Outcome
(41)
Colorectal Neoplasms - Drug Therapy
(39)
Aged, 80 And Over
(38)
Pharmacology. Drug Treatments
(37)
Tumors
(36)
Antineoplastic Agents
(35)
Cancer
(35)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(158)
Oncology
(27)
Jnci : Journal Of The National Cancer Institute
(12)
Seminars In Oncology
(12)
Investigational New Drugs
(11)
Plos One
(9)
Blood
(8)
Clinical Cancer Research
(8)
Journal Of The National Cancer Institute
(8)
The Oncologist
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cancer Stem Cells: The Promise and the Potential

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Development of an aerosol intervention for COVID-19 disease: Tolerability of soluble ACE2 (APN01) administered via nebulizer

Safety and Efficacy of Oxaliplatin and Fluoropyrimidine Regimens With or Without Bevacizumab As First-Line Treatment of Metastatic Colorectal Cancer: Results of the TREE Study

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study

Randomized Phase II Trial of Cetuximab, Bevacizumab, and Irinotecan Compared With Cetuximab and Bevacizumab Alone in Irinotecan-Refractory Colorectal Cancer: The BOND-2 Study

Routine DPYD Genetic Testing

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity

FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity

Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer

Combination of Immunotherapy and Radiation Therapy in Gastrointestinal Cancers: An Appraisal of the Current Literature and Ongoing Research

Chemotherapy Drug Shortages: It's Soluble

Drug Price Negotiations: One Long-Overdue "Small Step" for the American Health Care Consumer

PROSPECT: A Study Whose Time Is Past

The Painful Problem of Biosimilars in the Clinic

Updated Data and Groundbreaking Research Lead to an Exciting 2023 ASCO GI

Increasing Breast Cancer Diagnosis in Rural Areas and the Evolving Access to Health Care

2022 The Oncology Year in Review

Is Drug Price Negotiation a Concept Whose Time Has Come?

Platinum Hypersensitivity Reaction : An Ongoing Problem in Cancer Treatment

CRISPR Patent Battle: Beautiful Science, Poor Public Policy

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

Suchergebnisse filtern